Achieve Life Sciences, Inc. (ACHV) - 10-Q Summary
Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Overview: A late-stage clinical specialty pharmaceutical company focused on the development and commercialization of cytisinicline for smoking and e-cigarette cessation. The company has no approved products and has not generated product revenue to date.
Key Milestone: In September 2025, the FDA accepted the New Drug Application (NDA) for cytisinicline for smoking cessation, assigning a PDUFA action date of June 20, 2026. The company also received a Commissioner's National Priority Voucher (CNPV) for the vaping cessation indication in October 2025.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(14,441) | $(12,512) | $(39,986) | $(27,467) |
| Operating Expenses | $14,692 | $12,466 | $40,149 | $26,879 |
| Cash & Cash Equivalents | $31,930 | $12,753 | $31,930 | $12,753 |
| Marketable Securities | $16,184 | $21,607 | $16,184 | $21,607 |
| Total Liquidity (Cash + Securities) | $48,114 | $34,360 | $48,114 | $34,360 |
| Convertible Debt (Principal) | $10,000 | $10,000 | $10,000 | $10,000 |
| Working Capital | $40,325 | $29,785 | $40,325 | $29,785 |
Note: Revenue is $0 as the company has no commercial products. Liquidity includes cash, cash equivalents, and marketable securities.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, increased to $40.1 million from $26.9 million in the prior year period. This was driven by a $3.6 million increase in Research and Development (R&D) expenses (due to the ORCA-OL trial) and a $9.7 million increase in General and Administrative (G&A) expenses (due to commercial launch preparation and higher stock-based compensation).
- Capital Raising: In June 2025, the company completed a public offering raising approximately $45.2 million in gross proceeds ($45.2 million net of costs). This significantly improved cash balances compared to the prior year.
- Debt Refinancing: The company entered into a new convertible debt agreement with Silicon Valley Bank (SVB) in July 2024, refinancing prior debt. In October 2025 (subsequent event), the company drew down an additional $5.0 million tranche on this facility.
- Stock-Based Compensation: Stock-based compensation expense increased significantly to $7.5 million for the nine months ended September 30, 2025, compared to $4.1 million in the prior year period.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The company has disclosed substantial doubt about its ability to continue as a going concern. Current resources are insufficient to fund planned operations for the next 12 months. Continued operations depend on obtaining additional financing.
- Outlook: Management expects to incur significant expenses and increasing operating losses for the foreseeable future as they prepare for commercialization. They believe existing cash and marketable securities will fund operations into the second half of 2026, pending additional capital raises.
- Regulatory Risks: While the NDA for smoking cessation is under review, approval is not guaranteed. The FDA may require additional studies or issue a Complete Response Letter (CRL). The ongoing U.S. government shutdown poses a risk of delaying the review process.
- Supply Chain Dispute: The company has a dispute with its primary supplier, Sopharma, regarding the engagement of third-party manufacturers for the NDA. Sopharma alleges a breach of contract; the company disputes this. Resolution is critical for commercial supply.
- Debt Obligations: The company has $10.0 million in principal convertible debt outstanding (with potential for additional tranches). Failure to service this debt could lead to default and foreclosure on assets.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $48.1 million liquidity position against the projected burn rate for commercialization and the timeline to the June 2026 PDUFA date.
- Financing Plans: Confirm the status and terms of any planned equity or debt offerings required to bridge the funding gap beyond the second half of 2026.
- Supply Chain Resolution: Monitor the status of the dispute with Sopharma and the readiness of alternative third-party manufacturers to ensure commercial supply if FDA approval is granted.
- Regulatory Timeline: Track the impact of the U.S. government shutdown on the FDA's ability to meet the June 20, 2026, PDUFA action date.
- Dilution Risk: Assess the potential dilution from the outstanding convertible debt (convertible at $7.00/share for the first tranche) and approximately 34 million shares underlying outstanding warrants.